Stock Scorecard



Stock Summary for SpringWorks Therapeutics Inc (SWTX) - $37.44 as of 11/20/2024 8:45:29 PM EST

Total Score

9 out of 30

Currently on the following lists
None
Tim's Recommendation
Avoid

Growth List Algorithm Criteria for SWTX

Positive earnings growth
P/E ratio less than Industry P/E Ratio
P/E ratio less than Sector P/E Ratio
P/E ratio that is half the growth rate (or less)
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Positive net income past year and 12 trailing months
Free cash flow ratio greater than 0 and less than 10

Small Cap List Algorithm Criteria for SWTX

Revenue growing by at least 20% average per year over the last 5 years
Market Capitalization under 2 billion
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year

Dividend List Algorithm Criteria for SWTX

Declared an ex-dividend date
Forward annual dividend rate greater than 2
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Current ratio most recent quarter greater than 2
Cash Flow per Share greater than Trailing Dividend Rate

Bonus Criteria for SWTX

P/E ratio less than five-year Average P/E ratio
Last Price to 52 Week Low Ratio Less Than 1
Total Cash Per Share > Last Day Price
P/S Ratio < 1
P/B Ratio < 1

Safety Rating Criteria for SWTX (40 out of 90)

Stock Price Rating (Max of 10) 8
Historical Stock Price Rating (Max of 10) 9
Stock Price Trend (Max of 10) 2
Book Value (Max of 10) 4
Book Value to Price (Max of 10) 0
Analyst Buy Ratings (Max of 5) 4
Analyst Strong Buy Ratings (Max of 5) 4
Dividend Yield Percentage (Max of 10) 0
Operating Margin (Max of 10) 0
Trading Volume (Max of 10) 9
Price to Earnings (Max of 10) 0

Latest News for for SWTX

Does SpringWorks Therapeutics ( SWTX ) Have the Potential to Rally 92.68% as Wall Street Analysts Expect? 11/14/2024 2:55:00 PM
SpringWorks' Q3 Loss Narrower Than Expected, Revenues Miss Mark 11/13/2024 3:48:00 PM
SpringWorks Therapeutics to Participate in the Jefferies London Healthcare Conference - SpringWorks Therapeutics ( NASDAQ:SWTX ) 11/12/2024 2:25:00 PM
SpringWorks Therapeutics to Participate in the Jefferies London Healthcare Conference 11/12/2024 2:25:00 PM
SpringWorks Therapeutics ( SWTX ) Reports Q3 Loss, Lags Revenue Estimates 11/12/2024 12:45:00 PM
SpringWorks Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights 11/12/2024 11:30:00 AM
SpringWorks Therapeutics Announces Mirdametinib Data to be Presented at the 2024 Society for Neuro-Oncology ( SNO ) Annual Meeting - SpringWorks Therapeutics ( NASDAQ:SWTX ) 11/11/2024 12:00:00 PM
SpringWorks Therapeutics Announces Mirdametinib Data to be Presented at the 2024 Society for Neuro-Oncology ( SNO ) Annual Meeting 11/11/2024 12:00:00 PM
SpringWorks Therapeutics Announces Publication of the Pivotal Phase 2b ReNeu Trial Evaluating Mirdametinib in Adults and Children with NF1-PN in the Journal of Clinical Oncology 11/11/2024 11:30:00 AM
SpringWorks Therapeutics Announces Long-Term Efficacy and Safety Data from Phase 3 DeFi Trial of OGSIVEO® ( nirogacestat ) in Adults with Desmoid Tumors to be Presented at the Connective Tissue Oncology Society ( CTOS ) 2024 Annual Meeting - SpringWorks Therapeutics ( NASDAQ:SWTX ) 11/7/2024 11:30:00 AM

Financial Details for SWTX

Company Overview

Ticker SWTX
Company Name SpringWorks Therapeutics Inc
Country USA
Description SpringWorks Therapeutics, Inc. acquires, develops and markets drugs for underserved patient populations suffering from rare diseases and cancer. The company is headquartered in Stamford, Connecticut.
Sector Name LIFE SCIENCES
Industry Name BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
Most Recent Quarter 9/30/2024
Next Earnings Date N/A

Stock Price History

Last Day Price 37.44
Price 4 Years Ago 72.52
Last Day Price Updated 11/20/2024 8:45:29 PM EST
Last Day Volume 1,181,044
Average Daily Volume 1,208,159
52-Week High 53.92
52-Week Low 20.19
Last Price to 52 Week Low 85.44%

Valuation Measures

Trailing PE N/A
Industry PE 120.49
Sector PE 40.32
5-Year Average PE -22.32
Free Cash Flow Ratio 5.59
Industry Free Cash Flow Ratio 15.59
Sector Free Cash Flow Ratio 27.97
Current Ratio Most Recent Quarter 6.16
Total Cash Per Share 6.70
Book Value Per Share Most Recent Quarter 7.17
Price to Book Ratio 5.09
Industry Price to Book Ratio 5.50
Sector Price to Book Ratio 20.88
Price to Sales Ratio Twelve Trailing Months 18.97
Industry Price to Sales Ratio Twelve Trailing Months 20.11
Sector Price to Sales Ratio Twelve Trailing Months 7.11
Analyst Buy Ratings 4
Analyst Strong Buy Ratings 4

Share Statistics

Total Shares Outstanding 74,386,000
Market Capitalization 2,785,011,840
Institutional Ownership N/A

Dividends

Ex-Dividend Date N/A
Last Dividend Amount 0.00
Current Dividend Amount 0.00
Total Years Dividend Increasing N/A
Trailing Annual Dividend Rate 0.00
Trailing Annual Dividend Yield 0.00%
Forward Annual Dividend Rate 0.00
Forward Annual Dividend Yield 0.00%
5-Year Dividend Payments Count 0
3-Year Average Dividend Yield 0.00%
5-Year Average Dividend Yield 0.00%
1-Year Dividend Growth Rate Percentage 0.00%
3-Year Dividend Growth Rate Percentage 0.00%
5-Year Dividend Growth Rate Percentage 0.00%
All-Time Dividend Growth Rate Percentage 0.00%
Dividend Payout Ratio N/A

Income Statement

Quarterly Earnings Growth YOY 0.00%
Annual Earnings Growth -17.19%
Reported EPS 12 Trailing Months -3.89
Reported EPS Past Year -2.44
Reported EPS Prior Year -5.15
Net Income Twelve Trailing Months -275,156,000
Net Income Past Year -325,104,000
Net Income Prior Year -277,417,000
Quarterly Revenue Growth YOY 0.00%
5-Year Revenue Growth 0.00%
Operating Margin Twelve Trailing Months -1.18

Balance Sheet

Total Cash Most Recent Quarter 498,100,000
Total Cash Past Year 662,600,000
Total Cash Prior Year 597,000,000
Net Cash Position Most Recent Quarter 498,100,000
Net Cash Position Past Year 662,600,000
Long Term Debt Past Year 0
Long Term Debt Prior Year 0
Total Debt Most Recent Quarter 0
Equity to Debt Ratio Past Year 1.00
Equity to Debt Ratio Most Recent Quarter 1.00
Total Stockholder Equity Past Year 626,219,000
Total Stockholder Equity Prior Year 558,192,000
Total Stockholder Equity Most Recent Quarter 532,581,000

Free Cash Flow

Free Cash Flow Twelve Trailing Months -221,151,000
Free Cash Flow Per Share Twelve Trailing Months -2.97
Free Cash Flow Past Year -230,180,000
Free Cash Flow Prior Year -171,759,000

Options

Put/Call Ratio 0.20
Has Options Options Chain
Liquidity Rating

Technical Analysis

Yahoo Finance Chart Yahoo Finance Chart
MACD 0.29
MACD Signal -0.27
20-Day Bollinger Lower Band 28.22
20-Day Bollinger Middle Band 35.58
20-Day Bollinger Upper Band 42.94
Beta 0.79
RSI 59.26
50-Day SMA 39.89
150-Day SMA 34.52
200-Day SMA 44.73

System

Modified 11/19/2024 1:46:10 PM EST